The US mRNA therapeutics market size was estimated to be around US$ 11.07 billion in 2023 and is projected to reach US$ 38.21 billion by 2033, indicating a CAGR of 13.21% from 2024 to 2033.
Key Points
- By type, the prophylactic vaccines segment held the largest share of the market in 2023.
- By application, the infectious disease segment led the market in 2023. The segment is observed to sustain the growth rate during the forecast period.
- By end-use, the hospital and clinics segment held the largest share of the market in 2023. The segment is expected to sustain its position throughout the forecast period.
The market research report on the US mRNA therapeutics market provides a comprehensive analysis of various key aspects. It includes the definition, classification, and application of US mRNA therapeutics products. The report examines the development trends, competitive landscape, and industrial chain structure within the industry. Furthermore, it presents an overview of the industry, analyzes national policies and planning, and offers insights into the latest market dynamics and opportunities at a global level.
Get a Sample: https://www.precedenceresearch.com/sample/3862
US mRNA Therapeutics Market Scope
| Report Coverage | Details |
| Growth Rate from 2024 to 2033 | CAGR of 13.21% |
| U.S. Market Size in 2023 | USD 11.07 Billion |
| U.S. Market Size by 2033 | USD 38.21 Billion |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | By Type, By Application, and By End User |
Read More: Telecom Electronic Manufacturing Services Market Size, Share, Report By 2033
The report presents the volume and value-based market size for the base year 2023 and forecasts the market’s growth between 2023 and 2032. It estimates market numbers based on product form and application, providing size and forecast for each application segment in both global and regional markets.
Focusing on the global US mRNA therapeutics market, the report highlights its status, future forecasts, growth opportunities, key market players, and key market regions such as the United States, Europe, and China. The study aims to present the development of the US mRNA therapeutics market by considering factors like Year-on-Year (Y-o-Y) growth, in addition to Compound Annual Growth Rate (CAGR). This approach enables a better understanding of market certainty and the identification of lucrative opportunities.
Regarding production, the report investigates the capacity, production, value, ex-factory price, growth rate, and market share of major manufacturers, regions, and product types. On the consumption side, the report focuses on the regional consumption of US mRNA therapeutics products across different countries and applications.
Buyers of the report gain access to verified market figures, including global market size in terms of revenue and volume. The report provides reliable estimations and calculations for global revenue and volume by product type from 2024 to 2033. It also includes accurate figures for production capacity and production by region during the same period.
The research includes product parameters, production processes, cost structures, and data classified by region, technology, and application. Furthermore, it conducts SWOT analysis and investment feasibility studies for new projects.
This in-depth research report offers valuable insights into the US mRNA therapeutics market. It employs an objective and fair approach to analyze industry trends, supporting customer competition analysis, development planning, and investment decision-making. The project received support and assistance from technicians and marketing personnel across various links in the industry chain.
The competitive landscape section of the report provides detailed information on xx market competitors. It includes company overviews, financials, revenue generation, market potential, research and development investments, new market initiatives, global presence, production sites, production capacities, strengths and weaknesses, product launches, product range, and application dominance. However, the data points provided only focus on the companies’ activities related to the US mRNA therapeutics market.
Prominent players in the market are expected to face tough competition from new entrants. Key players are targeting acquisitions of startup companies to maintain their dominance. The report
Reasons to Purchase this Report:
- Comprehensive market segmentation analysis incorporating qualitative and quantitative research, considering the impact of economic and policy factors.
- In-depth regional and country-level analysis, examining the demand and supply dynamics that influence market growth.
- Market size in USD million and volume in million units provided for each segment and sub-segment.
- Detailed competitive landscape, including market share of major players, recent projects, and strategies implemented over the past five years.
- Comprehensive company profiles encompassing product offerings, key financial information, recent developments, SWOT analysis, and employed strategies by major market players.
US mRNA Therapeutics Market Companies
- GSK plc.
- BioNTech SE
- CureVac N.V.
- Sangamo Therapeutics, Inc.
- Translate Bio, Inc.
- Moderna, Inc.
- Argos Therapeutics Inc.
- Arcturus Therapeutics
- AstraZeneca plc.
- Pfizer Inc.
- CRISPR Therapeutics AG
Segments Covered in the Report
By Type
- Therapeutic Vaccines
- Prophylactic Vaccines
- Therapeutic Drugs
By Application
- Respiratory Diseases
- Oncology
- Rare Genetic Diseases
- Infectious Diseases
- Others
By End-use
- Research Organizations
- Hospitals & Clinics
- Others
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on US mRNA Therapeutics Market
5.1. COVID-19 Landscape: US mRNA Therapeutics Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global US mRNA Therapeutics Market, By Type
8.1. US mRNA Therapeutics Market, by Type, 2023-2032
8.1.1 Therapeutic Vaccines
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Prophylactic Vaccines
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Therapeutic Drugs
8.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global US mRNA Therapeutics Market, By Application
9.1. US mRNA Therapeutics Market, by Application, 2023-2032
9.1.1. Respiratory Diseases
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Oncology
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Rare Genetic Diseases
9.1.3.1. Market Revenue and Forecast (2020-2032)
9.1.4. Infectious Diseases
9.1.4.1. Market Revenue and Forecast (2020-2032)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global US mRNA Therapeutics Market, By End-use
10.1. US mRNA Therapeutics Market, by End-use, 2023-2032
10.1.1. Research Organizations
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Hospitals & Clinics
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Others
10.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global US mRNA Therapeutics Market, Trend Forecast
11.1. US
11.1.1. Market Revenue and Forecast, by Type (2020-2032)
11.1.2. Market Revenue and Forecast, by Application (2020-2032)
11.1.3. Market Revenue and Forecast, by End-use (2020-2032)
US mRNA Therapeutics Market
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on US mRNA Therapeutics Market
5.1. COVID-19 Landscape: US mRNA Therapeutics Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global US mRNA Therapeutics Market, By Type
8.1. US mRNA Therapeutics Market, by Type, 2024-2033
8.1.1 Therapeutic Vaccines
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Prophylactic Vaccines
8.1.2.1. Market Revenue and Forecast (2021-2033)
8.1.3. Therapeutic Drugs
8.1.3.1. Market Revenue and Forecast (2021-2033)
Chapter 9. Global US mRNA Therapeutics Market, By Application
9.1. US mRNA Therapeutics Market, by Application, 2024-2033
9.1.1. Respiratory Diseases
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Oncology
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Rare Genetic Diseases
9.1.3.1. Market Revenue and Forecast (2021-2033)
9.1.4. Infectious Diseases
9.1.4.1. Market Revenue and Forecast (2021-2033)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2021-2033)
Chapter 10. Global US mRNA Therapeutics Market, By End-use
10.1. US mRNA Therapeutics Market, by End-use, 2024-2033
10.1.1. Research Organizations
10.1.1.1. Market Revenue and Forecast (2021-2033)
10.1.2. Hospitals & Clinics
10.1.2.1. Market Revenue and Forecast (2021-2033)
10.1.3. Others
10.1.3.1. Market Revenue and Forecast (2021-2033)
Chapter 11. Global US mRNA Therapeutics Market, Trend Forecast
11.1. US
11.1.1. Market Revenue and Forecast, by Type (2021-2033)
11.1.2. Market Revenue and Forecast, by Application (2021-2033)
11.1.3. Market Revenue and Forecast, by End-use (2021-2033)
Chapter 12. Company Profiles
12.1. GSK plc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. BioNTech SE
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. CureVac N.V.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Sangamo Therapeutics, Inc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Translate Bio, Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Moderna, Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Argos Therapeutics Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Arcturus Therapeutics
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. AstraZeneca plc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Pfizer Inc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://www.expresswebwire.com/
Blog: https://www.uswebwire.com/
Blog: https://www.autoindustrybulletin.com/
